1-3 of 3
Takashi Kozakai, MD
Close
Sort by
Journal Articles

Log Reduction Levels of WT1 mRNA Expression in BM after Chemotherapies Are Predictive Markers of Good Prognosis in AML Patients Achieved CR after Induction Therapy

Yasuhiko Shibasaki, MD PhD, Yoshinobu Seki, MD PhD, Tomoyuki Tanaka, MD, Syukuko Miyakoshi, MD, Kyoko Fuse, MD, Takashi Kozakai, MD, Hironori Kobayashi, MD PhD, Takashi Ushiki, MD PhD, Takashi Abe, MD PhD, Toshio Yano, MD PhD, Masato Moriyama, MD PhD, Takashi Kuroha, MD PhD, Noriatsu Isahai, MD PhD, Jun Takizawa, MD, PhD, Miwako Narita, MD PhD, Satoru Koyama, MD PhD, Tatsuo Furukawa, MD PhD, Hirohito Sone, MDPhD, Masayoshi Masuko, MD PhD
Journal: Blood
Blood (2014) 124 (21): 2334.
https://doi.org/10.1182/blood.V124.21.2334.2334
Published: 2014
Journal Articles

Early Responses At 3 Months and 12 Months After Starting Imatinib As Predictive Factors For The Achievement Of Deep MR In Japanese CML Patients

Masayoshi Masuko, MD, PhD, Tatsuo Furukawa, MD, PhD, Tadashi Koike, MD, Kazue Takai, MD, Koichi Nagai, MD, Kenji Kishi, MD, PhD, Yoshinobu Seki, MD, Hoyu Takahashi, MD, PhD, Sadao Aoki, MD, PhD, Takashi Kozakai, MD, Yasuhiko Shibasaki, MD, Takashi Ushiki, MD, Ken Toba, MD, PhD, Miwako Narita, MD, PhD, Masuhiro Takahashi, MD, PhD, Hirohito Sone, MD, PhD, Akira Shibata, MD
Journal: Blood
Blood (2013) 122 (21): 2744.
https://doi.org/10.1182/blood.V122.21.2744.2744
Published: 2013
Journal Articles

Correlation Between Imatinib Trough Concentration and Long-Term Tolerability in CML Patients

Masayoshi Masuko, MD, PhD, Tatsuo Furukawa, MD, PhD, Toyoyuki Tanaka, MD, Syukuko Miyakoshi, MD, Takashi Kozakai, MD, Kyoko Fuse, MD, Yasuhiko Shibasaki, MD, Kazue Takai, MD, Yoshinobu Seki, MD, Masashi Kobayashi, MD, Koichi Nagai, MD, Hoyu Takahashi, MD, Kenji Kishi, MD, PhD, Miwako Narita, MD, PhD, Masuhiro Takahashi, Tadashi Koike, MD, Akira Shibata, MD
Journal: Blood
Blood (2012) 120 (21): 3751.
https://doi.org/10.1182/blood.V120.21.3751.3751
Published: 2012